Addex Therapeutics Ltd (ADXN)

Market Cap	12.11M
Revenue (ttm)	1.57M
Net Income (ttm)	-12.77M
Shares Out	1.54M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,472
Open	7.97
Previous Close	8.20
Day's Range	7.84 - 8.29
52-Week Range	5.00 - 27.90
Beta	1.87
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 6, 2024

About ADXN

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: ADXN

Financial Performance

In 2023, ADXN's revenue was 1.65 million, an increase of 13.99% compared to the previous year's 1.44 million. Losses were -10.56 million, -49.26% less than in 2022.

Financial numbers in CHF